Eversheds’ Madrid office has successfully represented pharmaceutical company MSD Spain in a landmark patent dispute, setting a new precedent for patent infringement cases.
The Madrid Commercial Court ordered generic drug companies Chemo Iberica and Quimica Sintetica to pay MSD Spain damages of €20m (£16m) for infringement of the Losartan patent. Losartan is commercially known as the hypertension medication Cozaar.
This ground-breaking decision represents the largest pharmaceutical patent infringement award in Spanish judicial history.
The Eversheds Nicea team, led by partners Kiko Carrión and José Mariano Cruz, acted for MSD Spain.